Lopinavir 100mg + ritonavir 25mg: Discontinuation
The lower strength combination tablet of lopinavir and ritonavir (Pharmacode 2613530) has been discontinued by the supplier.
Affected product
The supplier is discontinuing this strength of this product because no-one has needed them in the last two years and no-one is currently using them.
Lopinavir with ritonavir
- Presentation: Tab lopinavir 100 mg with ritonavir 25 mg
- Brand: Lopinavir/Ritonavir Mylan
- Pharmacode: 2613530
- Subsidy: $150.00
- Measure / Qty: per 60
Listed "Any brand" on the HML
The specific Mylan product is delisted from the Community Schedule and the Hospital Medicines List (HML).
This lower strength presentation will remain listed as "any brand" on the HML. We are also listing an oral liquid presentation as "any brand". This will allow hospitals to source these products, if needed.
Lopinavir 200 mg with Ritonavir 50 mg remains fully funded
The higher strength lopinavir 200mg + ritonavir 50mg tablets (Mylan) remain fully funded and available to everyone who needs them.
Clinical advice sought
Before deciding to delist the lower strength tablet, we sought advice from a range of clinicians. They advised that there are other, more preferred, options to treat HIV in children.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)
Pharmac is a government agency. We do not sell medicines or related products.